论文部分内容阅读
近年来随着内分泌激素研究的深入发展,特别是对多种下丘脑激素的分离鉴定和人工合成,为内分泌激素防治肿瘤开辟了新的前景。目前有关这方面的资料颇多,因限于篇幅,本文将摘要介绍下丘脑多肽激素促黄体释放素(LRH)和生长抑制素(SS)治疗前列腺癌、骨肉瘤、垂体腺瘤、乳腺癌、卵巢癌及女性生殖道肿瘤等方面的资料,以供参考。关于下丘脑激素LRH和SS的研究概况一、关于LRH的研究:LRH是首由Schally等在1971年从猪的下丘脑中被分离、鉴定现已能人工合成的一种下丘脑多肽激素,已证实为一小分子10肽化合物,具极强的生物活性,其微克量即可使垂体前叶释放足够数量的促性腺激素
In recent years, with the in-depth development of endocrine hormone research, especially the isolation, identification and artificial synthesis of multiple hypothalamic hormones, new prospects have been opened up for endocrine hormones to prevent and treat cancer. There is a lot of information in this area. Due to space limitations, this article will summarize the hypothalamic peptide hormone luteinizing hormone (LRH) and somatostatin (SS) in the treatment of prostate cancer, osteosarcoma, pituitary adenoma, breast cancer, and ovaries. Cancer and female genital tract tumors are provided for reference. Research on Hypothalamic Hormone LRH and SS 1. Research on LRH: LRH is a hypothalamic polypeptide hormone that was first synthesized by Schally et al. in 1971 and identified in the pig’s hypothalamus. It has been proved to be a small molecule of 10-peptide compound with extremely strong biological activity. The amount of microgram can release enough gonadotropin in the anterior pituitary gland.